BioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx (NASDAQ: BLRX) will release audited financial results for the year ended December 31, 2025 on March 23, 2026 before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX) will release audited financial results for the year ended December 31, 2025 on March 23, 2026 before U.S. markets open. Management will host a conference call on the same day at 8:30 a.m. EDT with CEO Philip Serlin.
Investors can join via dial-in (+1-888-281-1167 U.S.; +972-3-918-0685 international) or via a live webcast on the company website. A webcast replay will be posted about two hours after the call; a dial-in replay is available through March 25, 2026.
Details
News Market Reaction – BLRX
On Mar 16, the day this news came out, BLRX closed 1.50% below the previous close.
Data tracked by StockTitan Argus for the Mar 16 session.
Key Figures
- Results date
- March 23, 2026
- Audited results for year ended December 31, 2025
- Fiscal year end
- December 31, 2025
- Reporting period for upcoming annual results
- Conference call time
- 8:30 a.m. EDT
- Management earnings call on March 23, 2026
- U.S. dial-in
- +1-888-281-1167
- Access number for live conference call
- International dial-in
- +972-3-918-0685
- International access for live call
- Replay end date
- March 25, 2026
- Dial-in replay available until this date
- U.S. replay dial-in
- +1-888-295-2634
- Phone replay for conference call
- International replay dial-in
- +972-3-925-5904
- International phone replay for call
Previous Earnings date Reports
-
Set Q3 2025 results date and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial is expected to initiate in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2025-annual-results-on-march-23-2026-302714539.html
SOURCE BioLineRx Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.